309 related articles for article (PubMed ID: 31921375)
1. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Nishimatsu K; Komuta K
World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer.
Minami S; Ihara S; Tanaka T; Komuta K
World J Oncol; 2020 Feb; 11(1):9-22. PubMed ID: 32095185
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Aug; 11(4):139-149. PubMed ID: 32849954
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
[TBL] [Abstract][Full Text] [Related]
5. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors.
Lyu J; Yang N; Xiao L; Nie X; Xiong J; Liu Y; Zhang M; Zhang H; Tang C; Pan S; Liang L; Bai H; Li C; Kuang H; Li T
Front Nutr; 2023; 10():1113875. PubMed ID: 36969820
[TBL] [Abstract][Full Text] [Related]
7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.
Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
World J Oncol; 2017 Dec; 8(6):180-187. PubMed ID: 29317963
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
13. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy.
Yun NK; Rouhani SJ; Bestvina CM; Ritz EM; Gilmore BA; Tarhoni I; Borgia JA; Batus M; Bonomi PD; Fidler MJ
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804721
[TBL] [Abstract][Full Text] [Related]
15. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.
Xu C; Yao X; Li T; Wang J; An B; Wang J; Sui X; Leung EL; Wu Q
Transl Cancer Res; 2020 Apr; 9(4):2875-2883. PubMed ID: 35117644
[TBL] [Abstract][Full Text] [Related]
17. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Park S; Park S; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Kim YW; Heo DS
Korean J Intern Med; 2016 Nov; 31(6):1140-1149. PubMed ID: 27017943
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for
Gan Y; Ren J; Xian J; Yu H; Jin J; Li D; Li W
Int J Gen Med; 2022; 15():3405-3416. PubMed ID: 35378914
[TBL] [Abstract][Full Text] [Related]
19. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
